Elecoglipron is an investigational oral small molecule GLP-1 receptor agonist discovered by Eccogene and licensed to ...
MET-driven progression is associated with poor prognosis, and there remains a significant unmet need for effective and ...
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics company redefining protein ...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the United States Patent and Trademark Office (USPTO) has ...
The Options were granted as a material inducement to each employee’s employment and were approved by Definium's Compensation ...
Cochlear has a global workforce of more than 5,500 people with a passion for progress, who strive to meet the needs of people ...
NORTHRIDGE, Calif., Sept. 28, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today ...
DALLAS, Sept. 28, 2026 /PRNewswire/ -- Insera Therapeutics, Inc., a medical device company focused on advancing cyclical ...
Lupin's Apixaban Oral Suspension 1.25 mg/mL is an oral liquid formulation of apixaban, the active ingredient in Eliquis® ...
SkinCure Oncology, the leader in providing a comprehensive cancer center model for the delivery of Image-Guided Superficial ...
In the Phase 3 TEMPO program, AbbVie’s Juvmo elicited significant improvements in motor symptoms and prolonged periods with ...
Kodiak Sciences will head to regulators with one of the candidates, an anti-VEGF antibody called zenkuda, after the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results